Business Wire07.05.16
Bovie Medical Corporation has entered into a sales channel partnership Agreement with Arteriocyte Medical Systems Inc., to sell J-Plasma to its network of plastic surgeons.
The agreement will put Bovie’s innovative J-Plasma product in the hands of Arteriocyte’s U.S. sales network, significantly expanding its potential for use in office-based practices. Arteriocyte’s sales team has expertise in both biologics, and medical devices utilized in the plastic surgery category of care, and a portfolio of products that are complementary to J-Plasma.
Watch the video below for a demonstration of J-Plasma:
“We are delighted to sign this agreement with Arteriocyte, a company with an exemplary reputation in selling cellular therapy-based medical devices,” said Robert L. Gershon, CEO. “J-Plasma’s precision and lack of thermal spread make it a natural fit for the plastic surgeon, and Arteriocyte’s nationwide reach and complementary product portfolio will significantly raise awareness of the technology, and complement our existing sales efforts. This partnership is an important milestone in our strategy to scale J-Plasma across multiple specialties, leveraging the different applications for this unique surgical technology.”
Arteriocyte Medical Systems is a developer of healing technology solutions.
“J-Plasma’s potential to substantially reduce patient down-time aligns well with our strategic priorities, and we look forward to successfully launching this new product to our network of plastic surgeons nationwide,” said Donald Brown, CEO of Arteriocyte.
Bovie Medical Corporation is a manufacturer of medical devices and supplies as well as the developer of J-Plasma, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma uses a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation also manufactures a range of electrosurgical products and technologies, marketed through both private labels and the company’s own brands (Bovie, Aaron, IDS, and ICON). The company also leverages its expertise through original equipment manufacturing agreements with other medical device manufacturers.
The agreement will put Bovie’s innovative J-Plasma product in the hands of Arteriocyte’s U.S. sales network, significantly expanding its potential for use in office-based practices. Arteriocyte’s sales team has expertise in both biologics, and medical devices utilized in the plastic surgery category of care, and a portfolio of products that are complementary to J-Plasma.
Watch the video below for a demonstration of J-Plasma:
“We are delighted to sign this agreement with Arteriocyte, a company with an exemplary reputation in selling cellular therapy-based medical devices,” said Robert L. Gershon, CEO. “J-Plasma’s precision and lack of thermal spread make it a natural fit for the plastic surgeon, and Arteriocyte’s nationwide reach and complementary product portfolio will significantly raise awareness of the technology, and complement our existing sales efforts. This partnership is an important milestone in our strategy to scale J-Plasma across multiple specialties, leveraging the different applications for this unique surgical technology.”
Arteriocyte Medical Systems is a developer of healing technology solutions.
“J-Plasma’s potential to substantially reduce patient down-time aligns well with our strategic priorities, and we look forward to successfully launching this new product to our network of plastic surgeons nationwide,” said Donald Brown, CEO of Arteriocyte.
Bovie Medical Corporation is a manufacturer of medical devices and supplies as well as the developer of J-Plasma, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma uses a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation also manufactures a range of electrosurgical products and technologies, marketed through both private labels and the company’s own brands (Bovie, Aaron, IDS, and ICON). The company also leverages its expertise through original equipment manufacturing agreements with other medical device manufacturers.